Hepatocellular carcinoma

Current Opinion in Gastroenterology

Volumn 22, Issue 3, 2006, Pages 248-253

  Marrero, Jorge A ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alcohol; Diabetes; Hepatocellular carcinoma; Obesity; Surveillance

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ALPHA INTERFERON;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE MARKER; EARLY CANCER; EARLY DIAGNOSIS; HEALTH SURVEY; HEPATITIS C; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OBESITY; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TOBACCO;

ALGORITHMS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MASS SCREENING; PROGNOSIS; RISK FACTORS;

EID: 33746268104     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000218961.86182.8c     Document Type: Review

References (42)

1. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64:1263-1272.
2. Bosch X, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999; 19:271-285.
3. El-Serag HB, Mason AC. Increasing incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:345.
4. Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99:15584-15589.
5. Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127:1372-1380. A study that describes the increasing incidence of HCC in the USA and its relation to hepatitis C.
6. Kim WR, Gores GJ, Benson JT, et al. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 2005; 129:486-493.
7. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27:273-278.
8. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,700 men in Taiwan. Lancet 1981; 2:1129-1133.
9. Colombo M, Kuo G, Choo Q, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2:1006-1008.
10. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96:2462-2467.
11. Davila JA, Morgan RO, Shaib Y, et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54:533-539.
12. Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic factors for hepatocellular carcinoma. J Hepatol 2005; 42:218-224. This study evaluated whether alcohol, tobacco and obesity were synergistic.
13. Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97:293-300. Coffee reduces the risk of HCC in Japanese patients.
14. Kurozawa Y, Ogimoto I, Shibata A, et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005; 93:607-610.
15. Gelatti U, Covolo L, Franceschini M, et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005; 42:528-534.
16. Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142:105-114.
17. Bruix J, Sherma M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35:421-430.
18. Patel D, Terrault NA, Yao FY, et al. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005; 3:75-84.
19. Zhang BH, Yang BH, Tang ZY. Randomized controlled of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130:417-422. The first randomized trial of screening in hepatoma.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236. The official guidelines of the American Association for the Study of Liver Disease.
21. Di Bisceglie AM, Sterling AK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial. J Hepatol 2005; 43:434-441.
22. Paradis V, Degos F, Dargere D, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005; 41:40-47.
23. Schwegler EE, Cazares L, Steel LF, et al. SELDI-TOF profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41:634-642.
24. Block TM, Comunale MA, Lowman M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlated with liver cancer in wood-chucks and humans. Proc Natl Acad Sci USA 2005; 102:779-784.
25. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003; 67:138-145.
26. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42:27-34. Excellent study that evaluated vascularity in imaging and its utility in the diagnosis of HCC.
27. Marrero JA, Hussein HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005; 11:281-289. First study that evaluated washout of contrast for the diagnosis of HCC.
28. Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005; 25:171-180.
29. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41:707-716. First comparison of all staging systems for HCC.
30. Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing nonsurgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54:411-418.
31. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004; 40:124-131.
32. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8:765-774.
33. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11:1086-1092. A large series of liver resections for HCC.
34. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127:3277-3282.
35. Hwang S, Lee AG, Joh JW, et al. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and liver donor liver transplants. Liver Transpl 2005; 11:1265-1272.
36. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 2005; 234:961-967.
37. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240:900-909.
38. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41:1130-1137.
39. Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40:1352-1360. Important study on survival after percutaneous ablation.
40. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤ 4 cm. Gastroenterology 2004; 127:1714-1723. Randomized controlled trial of radiofrequency ablation.
41. Shiina S, Teratani T, Obi S, et al. A randomized controlled study of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129:122-130. Randomized controlled trial of radiofrequency ablation.
42. Lin Sm, Lin CJ, Lin CC, et al. Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection and percutaneous acetic acid injection to treat hepatocellular carcinoma 3 cm or less. Gut 2005; 54:1151-1156. Randomized controlled trial of radiofrequency ablation.